Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Receivables (2018 - 2025)

AVITA Medical's Receivables history spans 8 years, with the latest figure at $9.1 million for Q4 2025.

  • For Q4 2025, Receivables fell 22.91% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $9.1 million, down 22.91%, while the annual FY2025 figure was $9.1 million, 23.27% down from the prior year.
  • Receivables reached $9.1 million in Q4 2025 per RCEL's latest filing, up from $9.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $12.0 million in Q1 2025 to a low of $3.4 million in Q4 2021.
  • Average Receivables over 5 years is $7.1 million, with a median of $6.7 million recorded in 2023.
  • Peak YoY movement for Receivables: skyrocketed 204.4% in 2021, then plummeted 42.97% in 2022.
  • A 5-year view of Receivables shows it stood at $3.4 million in 2021, then increased by 28.81% to $4.4 million in 2022, then surged by 74.35% to $7.7 million in 2023, then soared by 53.18% to $11.8 million in 2024, then dropped by 22.91% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Receivables are $9.1 million (Q4 2025), $9.0 million (Q3 2025), and $11.3 million (Q2 2025).